Page last updated: 2024-11-07

6-hydroxydopa quinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-hydroxydopa quinone: structure given in first source; quinoid cofactor of quinoproteins; RN given refers to the 4-hydroxy-3,6-dioxo- tautomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-topaquinone : A topaquinone that has S configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123871
CHEBI ID36076
SCHEMBL ID1781673
MeSH IDM0185340

Synonyms (46)

Synonym
(s)-alpha-amino-4-hydroxy-3,6-dioxo-1,4-cyclohexadiene-1-propanoic acid
64192-68-3
(2s)-2-amino-3-(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)propanoic acid
CHEBI:36076
l-topaquinone
TPQ ,
topa quinone
5-(2-carboxy-2-aminoethyl)-2-hydroxy-1,4-benzoquinone
2,4,5-trihydroxyphenylalanine quinone
TOPAQUINONE ,
6-hydroxydopa quinone
6-hydroxyphenylalanine-3,4-dione
DB04334
(2s)-2-amino-3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)propanoic acid
1,4-cyclohexadiene-1-propanoic acid, alpha-amino-4-hydroxy-3,6-dioxo-, (s)-
cuprate(3-), [.mu.-[3-[[5-(aminosulfonyl)-2-(hydroxy-.kappa.o)phenyl]azo-.kappa.n1]-4-(hydroxy-.kappa.o)-7-[[[[5-hydroxy-6-[[2-(hydroxy-.kappa.o)-4-sulfophenyl]azo-.kappa.n1]-7-sulfo-2-naphthalenyl]amino]carbonyl]amino]-2-naphthalenesulfonato(7-)]]di-, tr
SCHEMBL1781673
(.alpha.s)-.alpha.-amino-6-hydroxy-3,4-dioxo-1,5-cyclohexadiene-1-propanoic acid
1,5-cyclohexadiene-1-propanoic acid, .alpha.-amino-6-hydroxy-3,4-dioxo-, (.alpha.s)-
1,5-cyclohexadiene-1-propanoic acid, .alpha.-amino-6-hydroxy-3,4-dioxo-, (s)-
PAG3GKA51Y ,
2',4',5'-topaquinone
135791-48-9
6-hydroxydopaquinone
AKOS030539942
(alphas)-alpha-amino-6-hydroxy-3,4-dioxo-1,5-cyclohexadiene-1-propanoic acid
1,5-cyclohexadiene-1-propanoic acid, alpha-amino-6-hydroxy-3,4-dioxo-, (alphas)-
1,5-cyclohexadiene-1-propanoic acid, alpha-amino-6-hydroxy-3,4-dioxo-, (s)-
unii-pag3gka51y
(s)-alpha-amino-6-hydroxy-3,4-dioxo-1,5-cyclohexadiene-1-propanoate
a-amino-6-hydroxy-3,4-dioxo-(as)-1,5-cyclohexadiene-1-propanoate
(s)-a-amino-6-hydroxy-3,4-dioxo-1,5-cyclohexadiene-1-propanoic acid
alpha-amino-6-hydroxy-3,4-dioxo-(as)-1,5-cyclohexadiene-1-propanoate
a-amino-6-hydroxy-3,4-dioxo-(as)-1,5-cyclohexadiene-1-propanoic acid
(s)-a-amino-6-hydroxy-3,4-dioxo-1,5-cyclohexadiene-1-propanoate
(s)-alpha-amino-6-hydroxy-3,4-dioxo-1,5-cyclohexadiene-1-propanoic acid
alpha-amino-6-hydroxy-3,4-dioxo-(as)-1,5-cyclohexadiene-1-propanoic acid
o-topaquinone
3-(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)-l-alanine
Q27896884
3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)alanine
DTXSID40982735
Q24063673
(s)-2-amino-3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)propanoic acid
PD006297
PD182936

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In addition, 2 mM GSH protected neurons from the toxic effects of 200 microM TOPA, but was not effective against 200 microM NMDA."( Glutathione prevents 2,4,5-trihydroxyphenylalanine excitotoxicity by maintaining it in a reduced, non-active form.
Aizenman, E; Boeckman, FA; Rosenberg, PA, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (141)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's73 (51.77)18.2507
2000's50 (35.46)29.6817
2010's18 (12.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.25 (24.57)
Research Supply Index4.98 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews26 (18.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other118 (81.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]